TCRX Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 10.44%, SMA50 6.3%, SMA200 -25.28%). The stock’s 14-day RSI is 59.46 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -56.81% below its high and over 25.79% above its low. Average 10-day trading volume of 888.96 thousand shares is in line with the 3-month average of 871.21 thousand, indicating normal recent market interest.

TScan Therapeutics, Inc. has 52.47 million shares outstanding. The public float is 44.03 million shares, elevated short interest at 3.97% of float. This equals 1.85 million shares. The short ratio is 6.82 days. Institutional investors hold 65.89% of the float. Insiders own 0.23%. Lynx1 Capital Management LP holds 8.02 million shares, BAKER BROS. ADVISORS LP has 4.02 million shares and Baker Brothers Life Sciences LP has 2.53 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

TScan Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.70. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that TScan Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 10.0%, with price expected at $1.10 by May 29, 2026, within a range of $1.02 to $1.19 3-Month Outlook: Projected fall of -75.0%, reaching $0.25 by August 13, 2026, with a range of $0.14 to $0.31. 1-Year Outlook: Projected loss of -4.0%, with price at $0.96 by May 14, 2027, within a range of $0.00 to $0.00.

TScan Therapeutics, Inc. generated EPS of -$1.12 over the past year. Five-year average earnings growth is -14.41%. Wall Street analysts project EPS growth of 6.48% annually over the next five years. The latest quarter delivered EPS of -$0.22. The next quarter is forecast at -$0.27. Next year's EPS is expected at $21.90. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $5.00. The high target offers 600.0% upside. The low target suggests 400.0% downside. The mean target is $6.00. This offers 500.0% upside. TScan Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 06, 2026, missed forecasts by 8.64%. The prior quarter beat by -33.33%. Over the last six quarters, Apple has recorded several small beats. These include 7.41% in March 05, 2025.

TScan Therapeutics, Inc. (NASDAQ:TCRX) shares are up 12.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows TScan Therapeutics, Inc. trading at a premium to the broader market with a P/E of -1.06. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $11.14, suggesting 1014.0% upside. Our AI forecast model points to short-term strength (10.0% over two weeks), a medium-term fall (-75.0% over three months), and a longer-term loss (-4.0% over one year), with expected trading ranges indicating moderate volatility.

TScan Therapeutics, Inc. (NASDAQ:TCRX) closed at $1.00 USD, losing -$0.11 (-9.91%) from the previous close of $1.11. The stock is currently mid-range between its 52-week high and low $0.88 and $2.57. With a market capitalization of about $61.07 million, TScan Therapeutics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.06). Key stats such as the average daily volume over the past year has been around 866.75 thousand shares, in line with its 52-week average. Headquartered in Waltham, MA, TScan Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Gavin MacBeath, the company employs approximately 200 people and listed since July 16, 2021. TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer.

TScan Therapeutics, Inc. trades at a P/E ratio of -1.06, slightly below the S&P 500 average, with a price-to-sales ratio of 6.77 and a price-to-book ratio of 1.36 suggesting the stock is closer to book value. The P/FCF stands at -0.49, also above market averages.